BioVie Inc. (BIVI) Financial Statements (2024 and earlier)
Company Profile
Business Address |
680 W NYE LANE CARSON CITY, NV 89703 |
State of Incorp. | NV |
Fiscal Year End | June 30 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | 12/31/2022 Q2 | 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 19,461 | 31,276 | 45,749 | 21,231 | 18,642 | 24,507 | |||
Cash and cash equivalents | 19,461 | 31,276 | 45,749 | 21,231 | 18,642 | 24,507 | |||
Other current assets | 285 | ||||||||
Other undisclosed current assets | 14,580 | 12,771 | 241 | 359 | 138 | ||||
Total current assets: | 34,041 | 44,047 | 45,990 | 21,590 | 18,780 | 24,792 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 81 | 91 | 100 | 109 | 118 | 127 | |||
Intangible assets, net (including goodwill) | 983 | 1,040 | 1,097 | 1,155 | 1,212 | 1,270 | |||
Goodwill | 346 | 346 | 346 | 346 | 346 | 346 | |||
Intangible assets, net (excluding goodwill) | 637 | 694 | 752 | 809 | 866 | 924 | |||
Other noncurrent assets | 5 | 5 | 5 | 5 | |||||
Total noncurrent assets: | 1,064 | 1,135 | 1,202 | 1,269 | 1,335 | 1,397 | |||
TOTAL ASSETS: | 35,105 | 45,183 | 47,192 | 22,859 | 20,115 | 26,188 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 3,525 | 5,033 | 3,245 | 2,622 | 2,443 | 3,528 | |||
Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1,161 | ||
Accounts payable | 3,476 | 4,839 | 3,245 | 2,622 | 2,443 | 1,206 | |||
Accrued liabilities | 48 | 194 | 1,161 | ||||||
Debt | 9,105 | 6,391 | |||||||
Other liabilities | 48 | 194 | 339 | 484 | 1,305 | 581 | |||
Other undisclosed current liabilities | 1,817 | 4,387 | 4,213 | 989 | 421 | 208 | |||
Total current liabilities: | 14,495 | 16,004 | 7,797 | 4,096 | 4,169 | 4,317 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 5,227 | 7,406 | 13,261 | 12,802 | 12,226 | 11,723 | |||
Long-term debt, excluding current maturities | 5,227 | 7,406 | 13,261 | 12,725 | 12,139 | 11,625 | |||
Liabilities, other than long-term debt | 43 | 54 | 66 | 48 | 194 | ||||
Other liabilities | 48 | 194 | |||||||
Operating lease, liability | 43 | 54 | 66 | 77 | 87 | 98 | |||
Other undisclosed noncurrent liabilities | (77) | ||||||||
Total noncurrent liabilities: | 5,270 | 7,460 | 13,327 | 12,802 | 12,274 | 11,916 | |||
Total liabilities: | 19,764 | 23,464 | 21,124 | 16,898 | 16,444 | 16,234 | |||
Equity | |||||||||
Equity, attributable to parent | 15,340 | 21,718 | 26,068 | 5,961 | 3,671 | 9,955 | |||
Common stock | 4 | 4 | 3 | 3 | 2 | 2 | |||
Treasury stock, value | (0) | (0) | |||||||
Additional paid in capital | 316,386 | 313,812 | 303,137 | 267,344 | 254,638 | 252,833 | |||
Accumulated other comprehensive income | 177 | 17 | |||||||
Accumulated deficit | (301,226) | (292,114) | (277,073) | (261,386) | (250,970) | (242,881) | |||
Total equity: | 15,340 | 21,718 | 26,068 | 5,961 | 3,671 | 9,955 | |||
TOTAL LIABILITIES AND EQUITY: | 35,105 | 45,183 | 47,192 | 22,859 | 20,115 | 26,188 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | 12/31/2022 Q2 | 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 2,119 | |||||||
Gain (loss) on disposition of assets for financial service operations | 2,717 | (366) | (3,222) | (567) | 2,119 | (386) | ||
Gross profit: | 2,119 | |||||||
Operating expenses | (10,977) | (13,775) | (11,495) | (8,834) | (9,292) | (5,749) | ||
Other undisclosed operating income (loss) | 366 | 3,222 | 567 | (2,119) | 386 | |||
Operating loss: | (10,977) | (13,775) | (11,495) | (8,834) | (9,292) | (5,749) | ||
Interest and debt expense | (1,108) | (1,083) | (1,053) | (1,056) | (927) | (919) | ||
Loss from continuing operations: | (12,084) | (14,857) | (12,548) | (9,891) | (10,219) | (6,667) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (9,891) | (10,219) | (6,667) | |
Other undisclosed net income (loss) | 2,972 | (184) | (3,139) | (525) | 3,331 | (373) | ||
Net loss: | (9,112) | (15,041) | (15,687) | (10,416) | (6,887) | (7,041) | ||
Other undisclosed net loss attributable to parent | (1,201) | |||||||
Net loss available to common stockholders, diluted: | (9,112) | (15,041) | (15,687) | (10,416) | (8,089) | (7,041) |
Comprehensive Income ($ in thousands)Annual | Quarterly
9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | 12/31/2022 Q2 | 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (9,112) | (15,041) | (15,687) | (10,416) | (6,887) | (7,041) | ||
Other comprehensive income (loss) | 160 | 17 | ||||||
Comprehensive loss, net of tax, attributable to parent: | (8,952) | (15,025) | (15,687) | (10,416) | (6,887) | (7,041) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.